1 |
Dixon, W. J. and Mode, A. M. (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-128.
DOI
|
2 |
Efron, B. (1971). Forcing a sequential experiment to be balanced, Biometrika, 58, 403-417.
DOI
|
3 |
Goodman, S. N., Zahurak, M. L., and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161.
DOI
|
4 |
Kang, S. (2002). Investigation on the modified continual reassessment method in phase I clinical trial, The Korean Journal of Applied Statistics, 15), 323-336.
DOI
|
5 |
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., and Simon, R. M. (1994). A comparison of two phase I trial designs, Statistics in Medicine, 13, 1799-1806.
DOI
|
6 |
Lee, N. and Kim, D. (2012). Two-stage maximum tolerated dose estimation by stopping rule in Phase I clinical trial, The Korean Statistical Society, 19, 57-64.
|
7 |
O'Quigley, J. and Chevret, S. (1991). Method for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664.
DOI
|
8 |
O'Quigley, J., Pepe, M. and Fisher, M. (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer, Biometrics, 46, 33-48.
DOI
|
9 |
O'Quigley, J. Shen, L.Z. (1996). Continual reassessment method: a likelihood approach , Biometrics, 52, 673-684.
DOI
|
10 |
Park, I. (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials (Master's Thesis of Science), The Catholic University of Korea.
|
11 |
Ahn, C. (1998). An evaluation of Phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537-1549.
DOI
|
12 |
Chevret, S. (1993). The continual reassessment method in cancer phase I clinical trials: a simulation study, Statistics in Medicine, 12, 1093-1108.
DOI
|
13 |
Lim, H. (2018). New Drug Development and Clinical Trials, Bullsbook.
|
14 |
Storer, B. E. (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937.
DOI
|
15 |
Storer, B. E. (2001). An evaluation of phase I clinical trial designs in the continuous dose response setting, Statistics in Medicine, 20, 2399-2408.
DOI
|